drugset / Trial / NCT04840888
A Study of LY3484356 in Healthy Female Participants
RandomizedCrossoverOpen-labelBasic science
Summary
The main purpose of this study is to evaluate the amount of LY3484356 that is found in the blood stream and how long the body takes to get rid of it when given with and without food. Participants are healthy females of non-childbearing potential. The study will also evaluate the tolerability and safety of LY3484356 by collecting the information about any side effects that may occur. The participant's involvement with the study will last approximately 27 days, not including screening.
Timeline
- Start
- 2021-04-26
- Primary completion
- 2022-04-12
- Completion
- 2022-04-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carbamazepine | Small molecule | 300 mg | Oral |
| Subject | Imlunestrant | Small molecule | 200 mg | Oral |
| Subject | Imlunestrant | Small molecule | 400 mg | Oral |
| Subject | Itraconazole | Small molecule | 200 mg | Oral |
| Subject | Midazolam | Small molecule | 1.2 mg | Oral |
| Subject | Omeprazole | Other / unclassified | 40 mg | Oral |
Indications
No indication recorded.